Welcome to our dedicated page for The Oncology Institute SEC filings (Ticker: TOIIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oncology Institute, Inc. filings document a public oncology-care company with Nasdaq-listed common stock under TOI and redeemable warrants under TOIIW. The warrant security is disclosed as exercisable, in whole-warrant form, for one share of common stock at an exercise price of $11.50 per share.
Recent Form 8-K reports furnish results of operations and financial-condition updates and record board-related governance events. Definitive proxy materials cover annual meeting procedures, shareholder voting matters and board governance for the company.
The Oncology Institute reported higher revenue driven by dispensary growth but remained unprofitable and reduced debt while cash declined. Total operating revenue rose to $119.8 million for the quarter and $224.2 million for the six months ended June 30, 2025, up from $98.6 million and $193.2 million a year earlier, led by a sharp increase in dispensary sales to $62.6 million for the quarter. The company reduced long-term debt (net) to $75.0 million after a partial prepayment and raised gross proceeds of about $16.5 million in a private placement.
Despite revenue growth, TOI recorded operating losses and a net loss of $17.0 million for the quarter and $36.6 million for the six months. Cash and cash equivalents fell to $30.3 million from $49.7 million at year-end 2024, though management states it has sufficient liquidity for at least one year. Non-operating items included a $7.3 million increase in the fair value of conversion option derivative liabilities and elimination of marketable securities by June 30, 2025. The consolidated financials include significant consolidated VIE balances, including VIE liabilities of $284.1 million for which creditors lack recourse to TOI’s general credit.
The Oncology Institute, Inc. furnished a press release that discloses its financial results and additional financial information for the three months ended June 30, 2025. The filing states the press release is provided as Exhibit 99.1 and clarifies that the information is being furnished rather than filed under the Exchange Act, limiting certain legal liabilities. The report lists the company’s registered securities (common stock: TOI; redeemable warrants: TOIIW) on Nasdaq and identifies the company as an emerging growth company. No detailed financial tables or specific line-item results are included in the 8-K text itself; readers must refer to Exhibit 99.1 for the full figures.
The Oncology Institute, Inc. reported that director Richard Barasch resigned from the Board, effective August 12, 2025, and the company states his resignation was not due to any disagreement with the company on operations, policies or practices. Anne McGeorge will replace Mr. Barasch as Chair of the Board, signaling an immediate leadership transition at the board level. The company furnished a press release dated August 13, 2025 as Exhibit 99.1 under Regulation FD. The Form 8-K does not disclose financial statements, material transactions, or earnings information.
Form 4 snapshot: On 07/24/2025 Oncology Institute, Inc. (TOI) director Richard A. Barasch reported a Code J transaction—an inter-entity distribution rather than an open-market trade. RAB Ventures (controlled by Barasch) transferred 287,756 common shares to member Boro Partners Fund 1 in proportion to Boro’s beneficial interest. The shares were moved at $0 consideration and therefore do not signal buying or selling pressure.
After the distribution, Barasch continues to hold 2,635,881 TOI shares indirectly through LLC structures and maintains no direct holdings. He disclaims investment control over Boro and any beneficial ownership beyond his pecuniary interest.
No derivative securities were reported and there were no changes to direct insider ownership. Given the internal nature of the transfer, the filing is generally viewed as administrative and is unlikely to have a material impact on TOI’s share valuation.
Director Richard A. Barasch of The Oncology Institute reported significant warrant exercise transactions on June 17, 2025. Through RAB Ventures (DFP) LLC, Barasch executed a cashless exercise of Common Warrants for 679,224 shares at an exercise price of $1.198 per share.
Key transaction details:
- Net received 368,096 shares of common stock through the cashless exercise
- Issuer withheld 311,128 shares for payment based on fair market value of $2.6154 per share
- Fair value calculated using 5-day volume weighted average price
- Total beneficial ownership after transaction: 2,923,637 shares held indirectly through LLC
The transaction was executed under a special waiver agreement allowing cashless exercise despite registration status, and is exempt under Rule 16b-6. The warrants had an expiration date of March 26, 2030.
Form 4 overview: Director Richard A. Barasch of The Oncology Institute, Inc. (TOI) reported two transactions converting Series A Common Stock Equivalent Preferred Stock into common shares.
- 06/17/2025: 1,595 preferred shares converted into 159,500 common shares. Post-conversion direct common ownership: 1,935,141.
- 06/18/2025: 6,204 preferred shares converted into 620,400 common shares, held indirectly by Helen Barasch Family Trust #1. Post-conversion indirect common ownership: 2,555,541.
Each preferred share converts into 100 common shares and carries no cash consideration, so the economic stake remains unchanged; the filing simply reclassifies equity from preferred to common. No shares were sold, and the director’s aggregate reported common holdings now total approximately 4.49 million (direct + indirect) when combining both ownership lines.
Potential implications for investors:
- The conversion adds 779,900 new common shares to the public float, creating modest dilution for existing shareholders.
- Because the insider retained all shares, the action may signal continued long-term commitment rather than profit-taking.
- No 10b5-1 trading plan was indicated for these specific transactions, and no cash changed hands.
The filing is routine for a preferred-to-common conversion and does not disclose earnings, operational updates, or strategic shifts. Investors should monitor subsequent filings to see whether the newly issued common shares are held or eventually sold.